Vivanza Biosciences (BOM:530057) Stock Based Compensation: ₹0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530057 Vivanza Biosciences Ltd BOM:530057
51 GF Score
Price ₹1.82
GF Value ₹23.40
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Vivanza Biosciences Stock Based Compensation?

Vivanza Biosciences BOM:530057 +5.20% 51 Stock Based Compensation is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:530057 with a GF Score™ of 51/100 and a GF Value™ of ₹23.40 (Possible Value Trap). The stock has 3 warning signs investors should review.

Vivanza Biosciences's Stock Based Compensation for the three months ended in Jun. 2026 was ₹0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0 Mil.

Vivanza Biosciences Stock Based Compensation Related Terms

Vivanza Biosciences Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Vivanza Biosciences's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivanza Biosciences Stock Based Compensation Chart

Vivanza Biosciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vivanza Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:530057
51GF Score
Vivanza Biosciences Ltd BOM:530057
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivanza Biosciences Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

What does a Stock Based Compensation of ₹0 Mil mean?
Vivanza Biosciences (BOM:530057) has a Stock Based Compensation of ₹0 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Vivanza Biosciences and its competitors.
Is Vivanza Biosciences' Stock Based Compensation too high?
Vivanza Biosciences' current Stock Based Compensation is ₹0 Mil. Overall, Vivanza Biosciences has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivanza Biosciences' Stock Based Compensation compare to ZTS?
Vivanza Biosciences' Stock Based Compensation of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Vivanza Biosciences and its competitors. Vivanza Biosciences's current Stock Based Compensation is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivanza Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Vivanza Biosciences (BOM:530057) is currently considered Possible Value Trap. The stock's GF Value™ is ₹23.40, compared to a current price of ₹1.82 — trading 92.2% below its estimated fair value. The current Stock Based Compensation is ₹0 Mil. Vivanza Biosciences' overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Vivanza Biosciences (BOM:530057), the current Stock Based Compensation is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivanza Biosciences (BOM:530057) Overvalued in 2026?

Based on GuruFocus' analysis, Vivanza Biosciences stock appears to be undervalued. The current stock price of ₹1.82 is trading 92.2% below its estimated GF Value™ of ₹23.40. GuruFocus considers Vivanza Biosciences to be Possible Value Trap.

Key valuation signals for BOM:530057:

  • Stock Based Compensation: ₹0 Mil
  • GF Value™: ₹23.40 vs. price of ₹1.82 (92.2% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the BOM:530057 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivanza Biosciences Business Description

Address S.G. Highway, 403/TF, Sarthik II, Opposite Rajpath Club, Bodakdev, Ahmedabad, GJ, IND, 380054
Vivanza Biosciences Ltd is a pharmaceutical company. Its core focus areas include research and development, manufacturing, and the distribution of a wide range of pharma and pharmaceutical products. The company's product portfolio includes Medical examination gloves, Injections, Veterinary feeds, and others.
51GF Score

Get the complete analysis for BOM:530057

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1.82
Price
₹23.40
GF Value